197892-14-1

Basic information

• Product Name: (S)-benzyl tert-butyl (4-hydroxybutane-1,3-diyl)dicarbamate
• Synonyms: (S)-benzyl tert-butyl (4-hydroxybutane-1,3-diyl)dicarbamate;(S)-2-(Boc-Amino)-4-(Z-Amino)-1-Butanol;(S)-2-(Boc-amino)-4-(Z-amino)-1-butanol≥ 99% (HPLC);Boc-Dab(Z)-ol;(S)-2-(Boc-Amino)-4-(Z-Amino)-1-Butanol(WX665076)
• CAS NO: 197892-14-1
• Molecular Formula: C₁₇H₂₆N₂O₅
• Molecular Weight: 338.39874
• Mol File: 197892-14-1.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (S)-benzyl tert-butyl (4-hydroxybutane-1,3-diyl)dicarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-benzyl tert-butyl (4-hydroxybutane-1,3-diyl)dicarbamate(197892-14-1)
• EPA Substance Registry System: (S)-benzyl tert-butyl (4-hydroxybutane-1,3-diyl)dicarbamate(197892-14-1)

Safety Data

• Hazardous Substances Data: 197892-14-1(Hazardous Substances Data)

Usage

Chemical Properties

White crystalline powder

Upstream product

• 3350-20-7 (2S)-4-(benzyloxycarbonyl)amino-2-(tert-butoxycarbonyl)aminobutyric acid 
• 16947-89-0 Boc-Dab(Z)-OH DCHA salt 
• 13726-85-7 Boc-Gln-OH 
• 25691-37-6 (2S)-4-amino-2-[(tert-butoxycarbonyl)amino]butanoic acid 
• 226212-75-5 methyl (2S) 2-N-tert-butyloxycarbonyl-4-N-benzyloxycarbonyl-(2,4)-diaminobutyrate 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 915714-91-9 (S)-4-benzyloxy-3-N-Boc-1-N'-Z-butane-1,3-diamine 
• 1007876-71-2 C₂₈H₃₈N₂O₆S 

Relevant articles and documents

Influence of pendant chiral Cγ-(alkylideneamino/guanidino) cationic side-chains of PNA backbone on hybridization with complementary DNA/RNA and cell permeability

Intrinsically cationic and chiral Cγ-substituted peptide nucleic acid (PNA) analogues have been synthesized in the form of γ(S)-ethyleneamino (eam)- and γ(S)-ethyleneguanidino (egd)-PNA with two carbon spacers from the backbone. The relative stabilization (ΔTm) of duplexes from modified cationic PNAs as compared to 2-aminoethylglycyl (aeg)-PNA is better with complementary DNA (PNA:DNA) than with complementary RNA (PNA:RNA). Inherently, PNA:RNA duplexes have higher stability than PNA:DNA duplexes, and the guanidino PNAs are superior to amino PNAs. The cationic PNAs were found to be specific toward their complementary DNA target as seen from their significantly lower binding with DNA having single base mismatch. The differential binding avidity of cationic PNAs was assessed by the displacement of DNA duplex intercalated ethidium bromide and gel electrophoresis. The live cell imaging of amino/guanidino PNAs demonstrated their ability to penetrate the cell membrane in 3T3 and MCF-7 cells, and cationic PNAs were found to be accumulated in the vicinity of the nuclear membrane in the cytoplasm. Fluorescence-activated cell sorter (FACS) analysis of cell permeability showed the efficiency to be dependent upon the nature of cationic functional group, with guanidino PNAs being better than the amino PNAs in both cell lines. The results are useful to design new biofunctional cationic PNA analogues that not only bind RNA better but also show improved cell permeability. (Graph Presented).

METHODS FOR INHIBITING DRUG DEGRADATION

Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters

COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450

Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters